August 11, 2025Journal of InfectionOpen Access

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial

View Full Paper

Ask AI

Bookmark

Authors

Discussion

COV-BOOST trial demonstrates successful immunogenicity and safety of heterologous COVID-19 vaccine schedules using NVX-CoV2373 and BNT162b2.

A BNT162b2 booster after two doses of NVX-CoV2373 significantly increased spike IgG titres and T-cell responses.
Participants showed a geometric mean IgG concentration of 216,255 ELU/mL at day 14, indicating strong immune response post-boost.
Assessment involved 3 doses of vaccines in a phase 3 trial, exploring immunogenicity and safety of heterologous schedules.
Safety assessments revealed mostly mild adverse events, supporting the viability of heterologous vaccination strategies.

Janani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

COV-BOOST trial demonstrates successful immunogenicity and safety of heterologous COVID-19 vaccine schedules using NVX-CoV2373 and BNT162b2.